Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy Targeting Neurofibromatosis or Schwannomatosis
NCT04085159Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- Whole Cell Cancer Vaccines, CAR-T Cells, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Beijing Boren Hospital autologous CAR-T therapy, allogeneic adenovirus-specific cytotoxic T lymphocytes, DCvac in neurofibromatosis (NF), schwannomatosis, sponsored by Shenzhen Geno-Immune Medical Institute. Started Jun 2026; status: terminated.
02
Drugs
Beijing Boren Hospital autologous CAR-T therapyallogeneic adenovirus-specific cytotoxic T lymphocytesDCvac
03
Conditions
neurofibromatosis (NF)schwannomatosis
Beyond the preview
Go deeper on NCT04085159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085159.